169 related articles for article (PubMed ID: 7579436)
1. Aggressive treatment for postcardiac transplant lymphoproliferation.
Swinnen LJ; Mullen GM; Carr TJ; Costanzo MR; Fisher RI
Blood; 1995 Nov; 86(9):3333-40. PubMed ID: 7579436
[TBL] [Abstract][Full Text] [Related]
2. Durable remission after aggressive chemotherapy for post-cardiac transplant lymphoproliferation.
Swinnen LJ
Leuk Lymphoma; 1997 Dec; 28(1-2):89-101. PubMed ID: 9498708
[TBL] [Abstract][Full Text] [Related]
3. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
4. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
[TBL] [Abstract][Full Text] [Related]
5. Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation.
Watts RG; Hilliard LM; Berkow RL
J Pediatr Hematol Oncol; 2002 Nov; 24(8):622-6. PubMed ID: 12439033
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
[TBL] [Abstract][Full Text] [Related]
7. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
9. Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
Chen YC; Ho CL; Kao WY; Hwang JM; Sheu LF; Chao TY
Ann Hematol; 2001 Nov; 80(11):647-52. PubMed ID: 11757723
[TBL] [Abstract][Full Text] [Related]
10. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
Gordon LI; Anderson J; Habermann TM; Winter JN; Glick J; Schilder RJ; Cassileth P
J Clin Oncol; 1996 Apr; 14(4):1275-81. PubMed ID: 8648384
[TBL] [Abstract][Full Text] [Related]
13. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.
Swinnen LJ; LeBlanc M; Grogan TM; Gordon LI; Stiff PJ; Miller AM; Kasamon Y; Miller TP; Fisher RI
Transplantation; 2008 Jul; 86(2):215-22. PubMed ID: 18645482
[TBL] [Abstract][Full Text] [Related]
16. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
[TBL] [Abstract][Full Text] [Related]
17. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
18. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
[TBL] [Abstract][Full Text] [Related]
19. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
20. [ProMACE-MOPP vs. ProMACE-CytaBOM polychemotherapies in the treatment of large-cell and unclassifiable non-Hodgkin's lymphomas].
Pieresca C; Gobbi PG; Bertoloni D; Grignani G; Rossi A; Legnani MC; Giordano M
Ann Ital Med Int; 1991; 6(3):267-72. PubMed ID: 1723289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]